Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239573 | 0.83 | TSHR (0.48) | CTSAACHEKDM4ETDP1TSHR | |
| SCHEMBL18239578 | 0.81 | CTSA (0.34) | CTSAACHEKDM4ETDP1TSHR | |
| SCHEMBL18239625 | 0.78 | LMNA (0.32) | CTSAACHE | |
| SCHEMBL18239655 | 0.78 | — | — | |
| SCHEMBL18235519 | 0.77 | TSHR (0.34) | TSHR | |
| SCHEMBL1832832 | 0.77 | SMPD1 (0.32) | KDM4ETDP1 | |
| SCHEMBL80155 | 0.75 | CTSA (0.56) | CTSAACHEKDM4ETDP1ALDH1A1 | |
| SCHEMBL18239576 | 0.75 | ALDH1A1 (0.41) | CTSAACHEALDH1A1 | |
| SCHEMBL18235523 | 0.75 | TSHR (0.40) | CTSAACHEALDH1A1TSHR | |
| SCHEMBL25311925 | 0.74 | CTSA (0.43) | CTSAACHEKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | CTSA 3774/4885ACHE 1571/4885KDM4E 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.